Generic Arimidex is used for treating breast cancer in women who have been through menopause, including women with disease progression after tamoxifen therapy. More info »
Yes, thankyou, I have recieved the order.
It arrived barely a week after I placed it, so your logistics is working
smoothly.
Thank you very much for a swift handling :)
Neoadjuvant Aromatase Inhibitor Therapy to Avoid Mastectomy - Medscape
Neoadjuvant Aromatase Inhibitor Therapy to Avoid MastectomyMedscapeThe investigators conducted a randomized, phase 2, open-label trial involving 374 postmenopausal women with ER-positive breast cancer to assess the effectiveness of 3 aromatase inhibitors: letrozole, anastrozole, and exemestane.
Prognostication and Prediction for ER-Positive Breast Cancer - Clinical Oncology News
Clinical Oncology NewsPrognostication and Prediction for ER-Positive Breast CancerClinical Oncology News2,3 In the IMPACT (Immediate Preoperative Anastrozole Tamoxifen or Combined with Tamoxifen) trial of 12 weeks of neoadjuvant tamoxifen versus anastrozole, total loss of ER expression during anastrozole therapy was not seen, and only three of 54 .
Increased Mammograms Up to 65% Responsible for Breast Cancer Mortality Reduction - SYS-CON Media (press release)
Increased Mammograms Up to 65% Responsible for Breast Cancer Mortality ReductionSYS-CON Media (press release)Drugs covered include: Abiraterone acetate (Zytiga), Afatinib (Tomtovok), Afimoxifene (TamoGel), Albumin-bound paclitaxel (Abraxane), Anastrozole (Arimidex), Apatinib, Bevacizumab (Avastin), Bosutinib, Capecitabine (Xeloda), Cediranib, .
Norton Rose Group | Pharma in brief - Canada: Federal Court of Appeal upholds ... - Linex Legal (press release) (registration)
Norton Rose Group | Pharma in brief - Canada: Federal Court of Appeal upholds .
An object clause is not necessarily determinative of the promise of the patent - Lexology (registration)
An object clause is not necessarily determinative of the promise of the patentLexology (registration)Analysis – The `420 Patent relates to (substituted-aralkyl) – heterocyclic compounds, including anastrozole, and in particular, to such compounds which are useful as inhibitors of the enzyme aromatase.